GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » NutraLife Biosciences Inc (OTCPK:NLBS) » Definitions » Cyclically Adjusted PS Ratio

NLBS (NutraLife Biosciences) Cyclically Adjusted PS Ratio : 0.01 (As of Apr. 25, 2025)


View and export this data going back to 2014. Start your Free Trial

What is NutraLife Biosciences Cyclically Adjusted PS Ratio?

As of today (2025-04-25), NutraLife Biosciences's current share price is $0.0001. NutraLife Biosciences's Cyclically Adjusted Revenue per Share for the quarter that ended in Sep. 2022 was $0.02. NutraLife Biosciences's Cyclically Adjusted PS Ratio for today is 0.01.

The historical rank and industry rank for NutraLife Biosciences's Cyclically Adjusted PS Ratio or its related term are showing as below:

NLBS's Cyclically Adjusted PS Ratio is not ranked *
in the Drug Manufacturers industry.
Industry Median: 2.01
* Ranked among companies with meaningful Cyclically Adjusted PS Ratio only.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

NutraLife Biosciences's adjusted revenue per share data for the three months ended in Sep. 2022 was $0.001. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $0.02 for the trailing ten years ended in Sep. 2022.

Shiller PE for Stocks: The True Measure of Stock Valuation


NutraLife Biosciences Cyclically Adjusted PS Ratio Historical Data

The historical data trend for NutraLife Biosciences's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NutraLife Biosciences Cyclically Adjusted PS Ratio Chart

NutraLife Biosciences Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

NutraLife Biosciences Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - 2.91

Competitive Comparison of NutraLife Biosciences's Cyclically Adjusted PS Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, NutraLife Biosciences's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NutraLife Biosciences's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, NutraLife Biosciences's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where NutraLife Biosciences's Cyclically Adjusted PS Ratio falls into.


;
;

NutraLife Biosciences Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

NutraLife Biosciences's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=0.0001/0.02
=0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NutraLife Biosciences's Cyclically Adjusted Revenue per Share for the quarter that ended in Sep. 2022 is calculated as:

For example, NutraLife Biosciences's adjusted Revenue per Share data for the three months ended in Sep. 2022 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Sep. 2022 (Change)*Current CPI (Sep. 2022)
=0.001/125.2265*125.2265
=0.001

Current CPI (Sep. 2022) = 125.2265.

NutraLife Biosciences Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201212 0.000 96.871 0.000
201303 0.003 98.209 0.004
201306 0.026 98.518 0.033
201309 0.009 98.790 0.011
201312 0.006 98.326 0.008
201403 0.001 99.695 0.001
201406 0.001 100.560 0.001
201409 0.000 100.428 0.000
201412 0.000 99.070 0.000
201503 0.000 99.621 0.000
201506 0.003 100.684 0.004
201509 0.002 100.392 0.002
201512 0.003 99.792 0.004
201603 0.002 100.470 0.002
201606 0.004 101.688 0.005
201609 0.001 101.861 0.001
201612 -0.001 101.863 -0.001
201703 0.004 102.862 0.005
201706 0.002 103.349 0.002
201709 0.009 104.136 0.011
201712 0.010 104.011 0.012
201803 0.009 105.290 0.011
201806 0.013 106.317 0.015
201809 0.012 106.507 0.014
201812 0.009 105.998 0.011
201903 0.007 107.251 0.008
201906 0.006 108.070 0.007
201909 0.004 108.329 0.005
201912 0.002 108.420 0.002
202003 0.001 108.902 0.001
202006 0.004 108.767 0.005
202009 0.001 109.815 0.001
202012 0.002 109.897 0.002
202103 0.001 111.754 0.001
202106 0.000 114.631 0.000
202109 0.000 115.734 0.000
202112 0.002 117.630 0.002
202203 0.000 121.301 0.000
202206 0.000 125.017 0.000
202209 0.001 125.227 0.001

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


NutraLife Biosciences  (OTCPK:NLBS) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


NutraLife Biosciences Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of NutraLife Biosciences's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


NutraLife Biosciences Business Description

Traded in Other Exchanges
N/A
Address
6601 Lyons Road, Suite L-6, Coconut Creek, FL, USA, 33073
NutraLife Biosciences Inc is engaged in the development, manufacturing and distribution of nutritional and dietary nutritional supplement products. The company is a branded and private label developer, manufacturer and distributor of a wide range of nutraceutical, wellness, and CBD products. It's private-label ingestible and skincare products include CBD-infused oral sprays, tinctures, pet drops, pain balms, and face creams. Its CBD products are derived from the seeds and mature stalks of the Cannabis Sativa plant which includes all parts and varieties of the cannabis sativa plant also known as hemp, which contain a tetrahydrocannabinol concentration.
Executives
Edgar Ward director, 10 percent owner, officer: President and CEO 5851 HOLMBERG RD., UNIT 2511, PARKLAND FL 33067
Neil Catania 10 percent owner, officer: Vice President 5 FIREPLACE CT., EAST NORTHPORT NY 11731
Lee White 10 percent owner, other: 10% Shareholder 130 S. RD., PAGET D0 PG06